Aviva
HRMY icon

Aviva’s Harmony Biosciences HRMY Stock Holding History

Aviva’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$479K Sell
13,168
-1,829
-12% -$57.7K ﹤0.01% 714
2026
Q1 		$420K Buy
14,997
+1,560
+12% +$51.2K ﹤0.01% 773
2025
Q4 		$503K Sell
13,437
-1,555
-10% -$51.1K ﹤0.01% 750
2025
Q3 		$413K Buy
14,992
+1,333
+10% +$45.9K ﹤0.01% 845
2025
Q2 		$432K Sell
13,659
-4,221
-24% -$136K ﹤0.01% 843
2025
Q1 		$593K Sell
17,880
-192
-1% -$6.88K ﹤0.01% 720
2024
Q4 		$622K Buy
18,072
+686
+4% +$23.6K ﹤0.01% 675
2024
Q3 		$695K Sell
17,386
-3,730
-18% -$131K ﹤0.01% 666
2024
Q2 		$637K Buy
21,116
+1,345
+7% +$40.4K ﹤0.01% 723
2024
Q1 		$664K Sell
19,771
-475
-2% -$15.2K ﹤0.01% 752
2023
Q4 		$654K Buy
+20,246
New +$565K ﹤0.01% 781

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aviva's HRMY Position: Q2 2026 in Review

Aviva reduced its Harmony Biosciences (HRMY) stake by 12% in Q2 2026, selling an estimated $57.7K and leaving 13,168 shares worth $479K. The position accounts for ﹤0.01% of the portfolio, ranked #714.

Aviva first reported a position in HRMY in Q4 2023 and has held it in 11 quarters since. The position peaked at $695K in Q3 2024. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Aviva held 13,168 shares of Harmony Biosciences worth $479K as of Q2 2026.
  • Aviva sold 1,829 Harmony Biosciences shares in Q2 2026, an estimated $57.7K.
  • Harmony Biosciences made up ﹤0.01% of Aviva's portfolio in Q2 2026, its #714 holding.
  • Aviva first reported a position in Harmony Biosciences in Q4 2023 and has held it in 11 quarters since.
  • Aviva's Harmony Biosciences position peaked at $695K in Q3 2024.
  • 328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.